Results 151 to 160 of about 7,007,196 (291)

Systematic profiling reveals broad G protein coupling and context‐dependent modulation of cyclic AMP by the orphan receptor GPR139

British Journal of Pharmacology, EarlyView.
Background and Purpose G protein‐coupled receptors (GPCRs) are major drug targets, yet many orphan receptors remain poorly characterized. GPR139 has been implicated in CNS disorders, including schizophrenia and depression, but its signalling mechanisms remain unclear.
Boris Trapkov, Hans Bräuner, Alexander Sebastian Hauser   +2 more
wiley   +1 more source

Postpartum retention in opioid agonist treatment for opioid dependence: A population-based cohort study. [PDF]

Arch Womens Ment Health
Zhou J, Varney B, Jones N, Bharat C, Degenhardt L, Havard A, Tran DT.   +6 more
europepmc   +1 more source

Signal detection and characterisation of a novel drug–drug interaction between methadone and a synthetic cannabinoid receptor agonist

British Journal of Pharmacology, EarlyView.
Background and Purpose Little is known about how synthetic cannabinoid receptor agonist (SCRA) co‐use with other psychoactive substances may exacerbate risk of death. This study aimed to characterise the polypharmacy of deaths where SCRAs were detected at post‐mortem, investigate the cardiotoxicity of SCRAs and probe their inhibition of human ether‐a ...
Kirsten L. Rock, Louise M. Hesketh, Hongwei Cheng, Shuoqi Chen, Simon Hudson, Graeme Henderson, Jules C. Hancox, Michael J. Shattock, Michael J. Curtis, Caroline S. Copeland   +9 more
wiley   +1 more source

An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol. [PDF]

Neuropsychopharmacology
P A Costa G, Sofuoglu M, Compton P, Ranganathan M, Pittman B, De Aquino JP.   +5 more
europepmc   +1 more source

The c‐Src inhibitor eCF506 diminishes opioid tolerance and reduces β‐arrestin2 recruitment

British Journal of Pharmacology, EarlyView.
Morphine activation of μ receptors causes tolerance through c‐Src activation and β‐arrestin2 recruitment. c‐Src inhibition or degradation reduces β‐arrestin2 recruitment, μ receptor endocytosis, while causing receptor upregulation, all likely contributing to reduced morphine tolerance.
Samuel Singleton, Fraser Nunn, Erika Lace, Álvaro Lorente‐Macías, Rachel Toth, Asier Unciti‐Broceta, Tim G. Hales   +6 more
wiley   +1 more source

Trends in Opioid Agonist Treatment for Opioid Dependence During Pregnancy: A Population-Based Study in New South Wales 2005-2021. [PDF]

Drug Alcohol Rev
Tran DT, Varney B, Jones N, Bharat C, Brett J, Oei JL, Pearson SA, Degenhardt L, Havard A.   +8 more
europepmc   +1 more source

Association between the location of Opioid Agonist Treatment (OAT) providers and heroin-related ambulance attendances. [PDF]

Subst Abuse Treat Prev Policy
Hall N, Rowland B, Ogeil RP, Loos R, Nehme Z, Lubman DI.   +5 more
europepmc   +1 more source

Canada Is in Urgent Need to Expand Opioid Agonist Treatment [PDF]

The Canadian Journal of Psychiatry, 2017
openaire   +2 more sources

Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To examine the association between initiation of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin.
Sangwoo Park, Seogsong Jeong, Hye Jun Kim, Dae Ho Lee, Soo Jung Choi, Sang Min Park   +5 more
wiley   +1 more source

Psychoactive prescription drug use and misuse in patients on opioid agonist treatment. [PDF]

Br J Clin Pharmacol
Soeiro T, Lacroix C, Jouve É, Frauger É, Lapeyre-Mestre M, Micallef J.   +5 more
europepmc   +1 more source